Drug Profile
Research programme: antifungals - Arietis Corporation
Alternative Names: 2-adamantanamine; AC 17Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Arietis Corporation
- Class Small molecules
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses(Combination therapy) in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses(Combination therapy) in USA (Topical)
- 12 Sep 2012 Preclinical trials in Mycoses in USA (PO)